On behalf of CoEHAR, the Center of Excellence for the acceleration of Harm Reduction, Dr. Lia Emma, researcher of the Replica project, will attend the conference to present the abstract "Cytotoxicity evaluation of vanillin in electronic cigarette liquids on human aortic artery endothelial cells”.
“𝑊𝑒 𝑛𝑒𝑒𝑑 𝑡𝑜 𝑐𝑜𝑙𝑙𝑎𝑏𝑜𝑟𝑎𝑡𝑒 𝑡𝑜𝑔𝑒𝑡ℎ𝑒𝑟 𝑠𝑜 𝑡ℎ𝑎𝑡 𝑒𝑣𝑒𝑟𝑦 𝑠𝑖𝑛𝑔𝑙𝑒 𝑎𝑟𝑡𝑖𝑐𝑙𝑒 𝑏𝑒𝑐𝑜𝑚𝑒𝑠 𝑎𝑛 𝑒𝑑𝑢𝑐𝑎𝑡𝑖𝑜𝑛𝑎𝑙 𝑡𝑜𝑜𝑙. 𝑊𝑒 𝑑𝑜𝑛'𝑡 𝑤𝑎𝑛𝑡 𝑡𝑜 𝑝𝑢𝑛𝑖𝑠ℎ 𝑎𝑢𝑡ℎ𝑜𝑟𝑠 𝑓𝑜𝑟 𝑡ℎ𝑒𝑖𝑟 𝑗𝑢𝑛𝑘 𝑝𝑎𝑝𝑒𝑟𝑠, 𝑤𝑒 𝑤𝑎𝑛𝑡 𝑡𝑜 𝑝𝑟𝑜𝑣𝑖𝑑𝑒 𝑡ℎ𝑒 𝑠𝑜𝑙𝑢𝑡𝑖𝑜𝑛 𝑡𝑜 𝑖𝑚𝑝𝑟𝑜𝑣𝑒”
The findings presented by CoEHAR researchers can contribute the discussions of ENDS for cessation and support harm reduction strategies in the world.
“However, it is important to understand a fact when talking about smoking: even today, nicotine is believed to play a major role in the developing of atherosclerosis” explains prof. Polosa “Nicotine does not cause atherosclerosis. In a survey conducted by SERMO on 1000 Italian doctors, it was found that 62 percent of the sample still think that atherosclerosis is caused by nicotine. The fact that 33 percent of the sample is made up of cardiologists is significant".
According the authors, for every 100 people, 10 to 19 are likely to quit using an e-cigarette; 12 to 16 using varenicline; and 10 to 18 using cytisine. This is compared to the 6 in 100 people likely to quit when using no medicine/e-cigarette or placebo. People using two forms of nicotine replacement therapy at the same time, for example, a combination of nicotine patch and nicotine gum, seemed to have similar rates of quitting to people using e-cigarettes, varenicline and cytisine.
According to prof. Riccardo Polosa, CoEHAR founder: "This small qualitative research simply found what we already knew: that young people are eager to explore new experiences, with vaping potentially being one of them. A critical limitation of this research is the absence of insights into how these participants have been educated about the health implications and addictive nature of nicotine/vaping. To work towards a smoke-free world, it's essential that our messaging on vaping's risk-to-benefit ratio is both accurate and truthful"
For the first time, CoEHAR researches reported a case of urticaria following the inhalation of a specific flavoring in an e-liquid used during a switching trial. Although linked to a specific component of the liquid used, this finding highlight the need of further regulation of e-liquid.
"We decided to provide the widest overview of clinical evidence on smoking submission and quit rates and absitance rates of e-cigarettes to researchers and clinicians” explain dr. Renèe O’Leary, author of the protocol.
On Monday 11 September, prof. Caponnetto has presented "Varenicline and counseling for vaping cessation: A double-blind, randomized, parallel-group, placebo-controlled trial".
The conference will bring together leading experts in the field to discuss the latest research on dyslipidemias and their management. Topics to be covered include the latest guidelines from the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS), as well as innovative topics such as environmental risk factors, including smoking, and their role in the progression of atherosclerosis.
We will send you direct emails, without intermediary services, you can withdraw any time.
Copyright 2021 – Center of Excellence for the acceleration of Harm Reduction. All rights reserved.